Findings

What do systematic reviews say?

32 questions · 32 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 7 · 21.9%Moderate 18 · 56.3%High 3 · 9.4%

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Outcomes (up to 2 years for primary outcomes) · primary immunosuppression in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

New onset of diabetes · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in new‐onset diabetes mellitus compared with calcineurin inhibitors (CNI): secondary outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 0.93 [0.69, 1.26]
13 studies · 2791 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Lymphoma/PTLD · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in lymphoma/PTLD compared with calcineurin inhibitors (CNI): secondary outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 2.47 [0.78, 7.86]
8 studies · 2537 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Tremor · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) leads to lower tremor compared with calcineurin inhibitors (CNI): secondary outcomes (high certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 0.25 [0.15, 0.41]
6 studies · 799 participants
High

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

GFR · primary immunosuppression in kidney transplant recipients

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
no estimate extracted
15 studies · 2983 participants
Low

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Cholesterol mg/dL · primary immunosuppression in kidney transplant recipients

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 579 participants
Low

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Serum fasting triglyceride (TG, mmol/L) · primary immunosuppression in kidney transplant recipients

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 843 participants
Low

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Thrombocytopenia · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with calcineurin inhibitors (CNI): secondary outcomes (low certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 5.26 [2.87, 9.63]
4 studies · 593 participants
Low

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Death (all causes) · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in death (all causes) compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 1.31 [0.87, 1.98]
19 studies · 3618 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Graft loss censored for death · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in graft loss censored for death compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 1.32 [0.96, 1.81]
14 studies · 3277 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Biopsy‐proven acute rejection · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) probably leads to higher biopsy‐proven acute rejection compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 1.7 [1.32, 2.19]
15 studies · 3309 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

CMV infection · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) leads to lower CMV infection compared with calcineurin inhibitors (CNI): main outcomes (high certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 0.43 [0.29, 0.63]
13 studies · 2026 participants
High

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Wound complications · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) probably leads to higher adverse wound outcomes: all complications compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 2.56 [1.94, 3.36]
12 studies · 1679 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

All malignancies · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in all malignancies compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 0.86 [0.5, 1.48]
10 studies · 2584 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Number needing to change treatment · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) probably leads to higher number needing to change treatment compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 2.42 [1.88, 3.11]
14 studies · 3148 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Outcomes (up to 2 years for secondary outcomes) · primary immunosuppression in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: primary outcomes

Outcomes (up to 2 years for primary outcomes) · primary immunosuppression in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: primary outcomes

Death (all causes) · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in death (all causes) compared with antimetabolites: primary outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 1.06 [0.84, 1.33]
31 studies · 10482 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: primary outcomes

Graft loss (censored) · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in graft loss (censored) compared with antimetabolites: primary outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 1.09 [0.82, 1.45]
26 studies · 8966 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: primary outcomes

Biopsy‐proven acute rejection · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in biopsy‐proven acute rejection compared with antimetabolites: primary outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 0.95 [0.81, 1.12]
24 studies · 10101 participants
Moderate